Johnson & Johnson vs Sea Limited — how do they compare? Johnson & Johnson trades at $260.64 (market cap $626.09B), while Sea Limited trades at $129.47 (market cap $80.55B). The key difference: Johnson & Johnson is far larger — about 7.8× Sea Limited's market cap, and Johnson & Johnson pays a 2.06% dividend while Sea Limited pays none. Which is the better fit depends on your goals.
| JNJ | SE | |
|---|---|---|
Market Cap | $626.09B | $80.55B |
Volume | 6,156,228 | — |
Sector | Health | Media |
52-Week High | $267.24 | $196.50 |
52-Week Low | $172.78 | $78.16 |
Enterprise Value | $654.37B | $75.58B |
Dividend Yield | 2.06% | — |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Sea Limited (SE) stock surged 12.11% to $128.7, driven by strong Q2 2026 results with revenue of $7.8 billion, up 48% year-over-year. The company demonstrated robust growth across e-commerce, fintech, and gaming segments, with net income rising 11% to $458 million. Technical indicators show a bullish trend, though RSI levels suggest overbought conditions. Analyst consensus remains positive with a $128.33 price target, supported by improved EBITDA guidance for Shopee.
The outlook for SE is favorable due to accelerating revenue growth and diversification, but risks include margin pressure from increased investments and credit costs. The stock's high P/E ratio of 50.78 demands sustained earnings expansion. Insider selling by the COO warrants monitoring. Overall, growth prospects outweigh near-term challenges, positioning SE for potential upside if execution continues.
Trailing returns across standard periods
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →